Literature DB >> 19891980

Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema.

J Morgenweck1, O S Abdel-Aleem, K C McNamara, R R Donahue, M Z Badr, B K Taylor.   

Abstract

Systemic administration of thiazolidinediones reduces peripheral inflammation in vivo, presumably by acting at peroxisome proliferator-activated receptor gamma (PPARgamma) in peripheral tissues. Based on a rapidly growing body of literature indicating the CNS as a functional target of PPARgamma actions, we postulated that brain PPARgamma modulates peripheral edema and the processing of inflammatory pain signals in the dorsal horn of the spinal cord. To test this in the plantar carrageenan model of inflammatory pain, we measured paw edema, heat hyperalgesia, and dorsal horn expression of the immediate-early gene c-fos after intracerebroventricular (ICV) administration of PPARgamma ligands or vehicle. We found that ICV rosiglitazone (0.5-50 microg) or 15d-PGJ(2) (50-200 microg), but not vehicle, dose-dependently reduced paw thickness, paw volume and behavioral withdrawal responses to noxious heat. These anti-inflammatory and anti-hyperalgesia effects result from direct actions in the brain and not diffusion to other sites, because intraperitoneal and intrathecal administration of rosiglitazone (50 microg) and 15d-PGJ(2) (200 microg) had no effect. PPARgamma agonists changed neither overt behavior nor motor coordination, indicating that non-specific behavioral effects do not contribute to PPAR ligand-induced anti-hyperalgesia. ICV administration of structurally dissimilar PPARgamma antagonists (either GW9662 or BADGE) reversed the anti-inflammatory and anti-hyperalgesic actions of both rosiglitazone and 15d-PGJ(2). To evaluate the effects of PPARgamma agonists on a classic marker of noxious stimulus-evoked gene expression, we quantified Fos protein expression in the dorsal horn. The number of carrageenan-induced Fos-like immunoreactive profiles was less in rosiglitazone-treated rats as compared to vehicle controls. We conclude that pharmacological activation of PPARgamma in the brain rapidly inhibits local edema and the spinal transmission of noxious inflammatory signals. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891980      PMCID: PMC2813335          DOI: 10.1016/j.neuropharm.2009.10.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  45 in total

Review 1.  Descending modulation in persistent pain: an update.

Authors:  Ke Ren; Ronald Dubner
Journal:  Pain       Date:  2002-11       Impact factor: 6.961

2.  Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.

Authors:  S Moreno; S Farioli-Vecchioli; M P Cerù
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

3.  A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation.

Authors:  H M Wright; C B Clish; T Mikami; S Hauser; K Yanagi; R Hiramatsu; C N Serhan; B M Spiegelman
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

Review 4.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

5.  Peroxisome proliferator-activated receptors and hepatic stellate cell activation.

Authors:  T Miyahara; L Schrum; R Rippe; S Xiong; H F Yee; K Motomura; F A Anania; T M Willson; H Tsukamoto
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

6.  Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners.

Authors:  Sebastian Fehlberg; Stefan Trautwein; Alexandra Göke; Rüdiger Göke
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

Review 7.  Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone.

Authors:  Torello Lotti; Beatrice Bianchi; Ilaria Ghersetich; Benedetta Brazzini; Jana Hercogova
Journal:  Int J Dermatol       Date:  2002-06       Impact factor: 2.736

8.  Stimulation of deep somatic tissue with capsaicin produces long-lasting mechanical allodynia and heat hypoalgesia that depends on early activation of the cAMP pathway.

Authors:  K A Sluka
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

9.  Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia.

Authors:  Bradley K Taylor; Niren Dadia; Carolyn B Yang; Sendhil Krishnan; Mostafa Badr
Journal:  Inflammation       Date:  2002-06       Impact factor: 4.092

10.  Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

Authors:  A G Nackley; A Makriyannis; A G Hohmann
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  26 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

2.  Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.

Authors:  Yang Yu; Bao-Jian Xue; Shun-Guang Wei; Zhi-Hua Zhang; Terry G Beltz; Fang Guo; Alan Kim Johnson; Robert B Felder
Journal:  Hypertension       Date:  2015-06-22       Impact factor: 10.190

3.  Genetic Deletion of Neuronal PPARγ Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPARγ Function.

Authors:  Esi Domi; Stefanie Uhrig; Laura Soverchia; Rainer Spanagel; Anita C Hansson; Estelle Barbier; Markus Heilig; Roberto Ciccocioppo; Massimo Ubaldi
Journal:  J Neurosci       Date:  2016-11-03       Impact factor: 6.167

Review 4.  PPARs and pain.

Authors:  Bright N Okine; Jessica C Gaspar; David P Finn
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

5.  Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission.

Authors:  Esi Domi; Francesca Felicia Caputi; Patrizia Romualdi; Ana Domi; Giulia Scuppa; Sanzio Candeletti; Alison Atkins; Markus Heilig; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo; Massimo Ubaldi
Journal:  J Neurosci       Date:  2019-11-04       Impact factor: 6.167

6.  Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.

Authors:  Ryan B Griggs; Renee R Donahue; Braxton G Adkins; Katie L Anderson; Olivier Thibault; Bradley K Taylor
Journal:  J Pain       Date:  2015-12-12       Impact factor: 5.820

7.  Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.

Authors:  Yang Yu; Zhi-Hua Zhang; Shun-Guang Wei; Robert M Weiss; Robert B Felder
Journal:  Hypertension       Date:  2011-11-14       Impact factor: 10.190

8.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

9.  Resolvin D1: A New Path to Unleash the Analgesic Potential of Peroxisome Proliferator-activated Receptor-γ for Postoperative Pain in Patients with Diabetes.

Authors:  Bradley K Taylor
Journal:  Anesthesiology       Date:  2015-12       Impact factor: 7.892

10.  Effects of long-term pioglitazone treatment on peripheral and central markers of aging.

Authors:  Eric M Blalock; Jeremiah T Phelps; Tristano Pancani; James L Searcy; Katie L Anderson; John C Gant; Jelena Popovic; Margarita G Avdiushko; Don A Cohen; Kuey-Chu Chen; Nada M Porter; Olivier Thibault
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.